ERBB2 and breast cancer: Pertuzumab in combination with trastuzumab and docetaxel had the approval of the U.S. Food and Drug Administration (FDA) for the treatment of metastatic breast cancer [60] and for the use as neoadjuvant therapy in case of the patients with HER-2 positive breast cancer [61].